Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2+ Metastatic Breast Cancer (MBC)”

149 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 149 results

Post-approval studies (Phase 4)UnknownNCT05131841
What this trial is testing

Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC

Who this might be right for
Metastatic Breast Cancer
Zhejiang Cancer Hospital 60
Testing effectiveness (Phase 2)Looking for participantsNCT06324357
What this trial is testing

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Who this might be right for
Metastatic Breast CancerMetastatic Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma+2 more
Boehringer Ingelheim 768
Not applicableUnknownNCT04852081
What this trial is testing

Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.

Who this might be right for
Breast Cancer Stage IV
Blokhin's Russian Cancer Research Center 1,000
Testing effectiveness (Phase 2)UnknownNCT04262804
What this trial is testing

Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Who this might be right for
Breast Cancer Metastatic
Zai Lab (Shanghai) Co., Ltd. 123
Large-scale testing (Phase 3)Study completedNCT01619111
What this trial is testing

DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs

Who this might be right for
HER2-negative Metastatic Breast CancerHER2-positive Circulating Tumor Cells
Prof. Wolfgang Janni 105
Testing effectiveness (Phase 2)Looking for participantsNCT06369831
What this trial is testing

HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011

Who this might be right for
Metastatic Breast CancerMetastatic Solid Cancer
Abscint NV/SA 60
Large-scale testing (Phase 3)UnknownNCT02404051
What this trial is testing

Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerBreast CancerHormone Receptor Positive Tumor+2 more
Consorzio Oncotech 745
Large-scale testing (Phase 3)UnknownNCT02344472
What this trial is testing

Detect V / CHEVENDO (Chemo vs. Endo)

Who this might be right for
Metastatic Breast Cancer
Prof. Wolfgang Janni 271
Not applicableStudy completedNCT05505175
What this trial is testing

Outcomes Among Patients in Brazil Receiving Palbociclib Combinations for HR+/HER2- MBC

Who this might be right for
Breast CancerBreast Carcinoma
Pfizer 121
Not applicableStudy completedNCT04566458
What this trial is testing

RWD Study in HER2+ mBC Patients in Third-Line Therapy

Who this might be right for
Breast Cancer Stage IV
Exactis Innovation 63
Not applicableLooking for participantsNCT06983691
What this trial is testing

Patient Navigation for HER2+ Metastatic Breast Cancer Patients Treated With Tucatinib

Who this might be right for
HER2+ Metastatic Breast Cancer (MBC)
Duke University 26
Early research (Phase 1)Study completedNCT02001974
What this trial is testing

Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)

Who this might be right for
Metastatic Breast Cancer
Dompé Farmaceutici S.p.A 33
Testing effectiveness (Phase 2)UnknownNCT02175446
What this trial is testing

Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients

Who this might be right for
Metastatic Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast
Consorzio Oncotech 61
Testing effectiveness (Phase 2)Study completedNCT00915603
What this trial is testing

Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
SCRI Development Innovations, LLC 113
Not applicableLooking for participantsNCT06774027
What this trial is testing

Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer

Who this might be right for
HER2-negative Breast CancerHER2 Negative Breast CarcinomaMetastatic Breast Cancer+3 more
University of California, San Francisco 100
Early research (Phase 1)Looking for participantsNCT06784193
What this trial is testing

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)+3 more
Olema Pharmaceuticals, Inc. 180
Early research (Phase 1)Study completedNCT01482156
What this trial is testing

Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsMetastatic Breast CancerMetastatic Renal Cell Carcinoma
Novartis Pharmaceuticals 46
Testing effectiveness (Phase 2)WithdrawnNCT01479179
What this trial is testing

Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center
Large-scale testing (Phase 3)UnknownNCT04385563
What this trial is testing

Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.

Who this might be right for
HER2-positive Metastatic Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 338
Early research (Phase 1)Ended earlyNCT01805908
What this trial is testing

Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC)

Who this might be right for
Breast Cancer
Ontario Clinical Oncology Group (OCOG) 3
Next Page